ACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease
| Autor: | K Bharani, T.S. Mohamed Saleem, K Gauthaman |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Angiotensin receptor renin angiotensin system Combination therapy End organ damage business.industry lcsh:Medical emergencies. Critical care. Intensive care. First aid Disease lcsh:RC86-88.9 Review Emergency Nursing Pharmacology angiotensin II medicine.disease Angiotensin II angiotensin receptor blockers Endocrinology Tolerability Internal medicine Renin–angiotensin system Emergency Medicine medicine Pharmaceutical sciences business |
| Zdroj: | Open Access Emergency Medicine : OAEM Open Access Emergency Medicine, Vol 2010, Iss default, Pp 51-59 (2010) |
| ISSN: | 1179-1500 |
| Popis: | T S Mohamed Saleem1, K Bharani1, K Gauthaman21Department of Pharmacology, Annamacharya College of Pharmacy, Rajampet-516126, Kadapa Dist, Andhra Pradesh, India; 2Department of Drug Technology, Higher Institute of Medical Technology, Derna, LibyaAbstract: Morbidity and mortality from cardiovascular diseases are still high, even with the use of the best available therapies. There is mounting evidence that excessive renin-angiotensin system activation triggers much of the damaging and progressive nature of cardiovascular and kidney diseases through expression of angiotensin II. Moreover, angiotensin II play a major role in the development of end organ damage through a variety of inflammatory mechanisms. Today, angiotensins-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists have clearly demonstrated their efficacy in preventing target organ damage and in reducing cardiovascular morbidity and mortality in ischemic heart disease (IHD). Moreover, the development of angiotensin II receptor antagonists has enabled a large gain in tolerability and safety. Several clinical trials have firmly established that these drugs act on the renin–angiotensin system, reducing the incidence of coronary events with monotherapy and combination therapy. In this review we summarize the role mono- and combined therapy of ACE inhibitors and angiotensin II receptor antagonists play in ischemic heart disease. In this respect the review will improve ideas for developing new formulations with combinations of these drugs in the future.Keywords: angiotensin receptor blockers, renin angiotensin system, angiotensin II |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|